CD74-ROS1 fusion
|
Malignant Pleural Mesothelioma
|
CD74-ROS1 fusion
|
Malignant Pleural Mesothelioma
|
crizotinib Sensitive: C4 – Case Studies
J Cancer Res Clin Oncol - 3 weeks (New C4)
|
crizotinib Sensitive: C4 – Case Studies
J Cancer Res Clin Oncol - 3 weeks - (New C4)
|
CD74-ROS1 fusion
|
NSCLC
|
CD74-ROS1 fusion
|
NSCLC
|
AB-106 Sensitive: C2 – Inclusion Criteria
|
AB-106 Sensitive: C2 – Inclusion Criteria
|
CD74-ROS1 fusion
|
NSCLC
|
CD74-ROS1 fusion
|
NSCLC
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
CD74-ROS1 fusion
|
NSCLC
|
CD74-ROS1 fusion
|
NSCLC
|
TPX-0005 Resistant: C4 – Case Studies
|
TPX-0005 Resistant: C4 – Case Studies
|
CD74-ROS1 fusion
|
LUAD
|
CD74-ROS1 fusion
|
LUAD
|
cisplatin + pemetrexed Sensitive: C4 – Case Studies
|
cisplatin + pemetrexed Sensitive: C4 – Case Studies
|
CD74-ROS1 fusion
|
LUAD
|
CD74-ROS1 fusion
|
LUAD
|
entrectinib Sensitive: C4 – Case Studies
|
entrectinib Sensitive: C4 – Case Studies
|
CD74-ROS1 fusion
|
Lung Cancer
|
CD74-ROS1 fusion
|
Lung Cancer
|
gilteritinib Sensitive: D – Preclinical
|
gilteritinib Sensitive: D – Preclinical
|